FTC requires Lupin, Gavis to divest drugs for deal approval

February 19, 2016 4:46 PM

1 0

Feb 19 Lupin Ltd and Gavis Pharmaceuticals LLC must divest two drugs for the Indian generic drugmaker's proposed $880 million acquisition of Gavis to go through, the U.S. Federal Trade Commission said.

The FTC's proposed consent order requires the companies to divest the drugs, used to treat bacterial infections and ulcerative colitis, to G&W Laboratories to address anticompetetive concerns. (1.usa.gov/1QOj0su)

Also read: FDA staff flags concerns about Allergan, Serenity Pharma urinary drug

Read more

To category page